Shingles Vaccination in Medicare Part D After Inflation Reduction Act Elimination of Cost Sharing

Dima M Qato; John A Romley; Rebecca Myerson; Dana Goldman; A Mark Fendrick

doi:10.1001/jama.2024.7348

Shingles Vaccination in Medicare Part D After Inflation Reduction Act Elimination of Cost Sharing

JAMA. 2024 Jun 18;331(23):2043-2045. doi: 10.1001/jama.2024.7348.

Authors

Dima M Qato^{1

2}, John A Romley^{2

3}, Rebecca Myerson^{2

4}, Dana Goldman^{2

3}, A Mark Fendrick⁵

Affiliations

¹ Program on Medicines and Public Health, University of Southern California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, Los Angeles.
² Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles.
³ Sol Price School of Public Policy, University of Southern California, Los Angeles.
⁴ Department of Population Health Sciences, University of Wisconsin-Madison.
⁵ Center for Value-Based Insurance Design, University of Michigan, Ann Arbor.

No abstract available

Plain language summary

This cross-sectional study uses data from retail pharmacies to examine shingles vaccine uptake among Medicare Part D beneficiaries following an IRA policy to eliminate cost sharing.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Cost Sharing* / economics
Herpes Zoster Vaccine* / economics
Herpes Zoster* / prevention & control
Humans
Medicare Part D* / economics
Medicare Part D* / legislation & jurisprudence
United States
Vaccination / economics
Vaccination / legislation & jurisprudence

Substances

Herpes Zoster Vaccine

Plain language summary

Publication types

MeSH terms

Substances

Grants and funding